Latest news with #Gaithersburg
Yahoo
19 hours ago
- General
- Yahoo
Two injured in Gaithersburg assault, police investigating
GAITHERSBURG, Md. (DC News Now) — The Gaithersburg Police Department is investigating after two people were injured during an assault on Saturday. Police say the incident occurred on Bureau Drive just before 7 p.m. when a group of four to six people assaulted two adults. Two hurt in crash involving Montgomery County Fire and Rescue Service tanker According to police, the victims sustained blunt force trauma from the encounter. Anyone with information is asked to call detectives at (301) 258-6400 or the Tip Line at (301) 330-4471. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
a day ago
- General
- Yahoo
Two hospitalized in Gaithersburg crash
GAITHERSBURG, Md. (DC News Now) — Two people were hospitalized after a Saturday crash in Gaithersburg, according to the Montgomery County Department of Police. Officers responded shortly after 8:30 a.m. to reports of a 'serious' crash westbound on Sam Eig Highway at Fields Road. Two charged in connection with body found in burning car in Anne Arundel County There, two cars were found involved in a crash, and an initial investigation determined that a Jeep Compass struck a Toyota Corolla. Both drivers were transported to the hospital with non-life-threatening injuries, police say. The crash remains under investigation. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Daily Mail
21-05-2025
- Health
- Daily Mail
Haunting movement that people make just before they die - and the fascinating reason behind it, nurse reveals
If your loved one on hospice suddenly appears to reach up to the sky or ceiling at the end of their life, you're not just imagining it. For the 'unexplainable phenomenon' is 'really common' among people on the verge of death, experts have claimed. Katie Duncan, from Gaithersburg in Maryland, said the upward movement will often catch relatives off guard but patients are in fact reaching towards dead relatives, friends or even a cherished pet. While this can make it look like the dying person is in distress, she said it doesn't cause a patient to suffer. The nurse practitioner and end-of-life coach has worked in intensive care, home hospices and community and rehab facilities, caring for terminally-ill patients in the months leading up to their death. Now, she shares videos on social media on what she says she has learnt about death and dying, in the hopes of destigmatising it. In the clip, seen more than five million times, she said: 'This is one of those unexplainable phenomenons. In my personal experience working with people who are dying, this reach towards someone or something above them is really common. 'Sometimes this is associated with what we call end of life visions or other end of life experiences. 'When someone vocalises seeing someone or something, often it's an angel, sometimes it's a bright light. 'Very commonly, they say it is a loved one or family member or pet, someone who has died before. 'The person who is dying is vocalising that they're seeing this person. But sometimes you see a person reach and they don't say anything at all.' Clips of patients in their final moments have been widely shared on social media sites including TikTok and Instagram. Responding to Ms Duncan's video, TikTok users spoke about their own experiences. 'My husband did this also he reached both arms out and said mom the biggest smile I ever seen him smile,' one wrote. 'My dad saw a little boy on a white horse the night before he passed,' another said. In a separate Instagram reel seen over one million times, one woman also shared a video of her husband reaching up towards the ceiling as he drank water. 'I was so happy he was drinking I didn't even notice he was doing the before death reach to the sky,' she said. It's unclear exactly what causes terminal lucidity. However, one US study published in 2023 looking at brain activity during death suggested that dying brains are deprived of oxygen and may produce increased gamma wave activity. Gamma waves are the fastest brain waves, which occur when patients are highly alert and actively processing sensory information. Experts also believe the brain releases a flood of neurotransmitters like serotonin right before death, which could improve mood. Ms Duncan also said: 'What should we be doing about this reach? Nothing. It's one of those mystical parts of the dying process that we are able to be a witness to. 'We also know that other end of life visions and experiences tend to bring the dying person a lot of peace and comfort. 'If you're a loved one who's witnessing this in your dying person, I hope that you can let it bring you comfort.'
Yahoo
19-05-2025
- Health
- Yahoo
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025. RECLAIM is a randomized, placebo-controlled trial being conducted at approximately 15 sites in the United States, with Dr. Henry Kranzler, Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction at the University of Pennsylvania Perelman School of Medicine, serving as the Principal Investigator. The trial is expected to enroll approximately 100 subjects randomized 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks. The primary endpoint of the trial is a change in alcohol consumption, assessed as the change from baseline in the average number of heavy drinking days per week at Week 24, with the key secondary endpoints including the proportion of subjects achieving a 2-level reduction in World Health Organization (WHO) risk drinking level and the absolute change from baseline in average levels of phosphatidylethanol (PEth), a serum biomarker of alcohol intake. An investigational new drug (IND) application for pemvidutide in AUD was filed in December 2024 and was cleared by FDA in January 2025. 'Over 28 million individuals in the U.S. alone have AUD, and the lack of effective treatments has resulted in one of the largest known treatment gaps in this country,' said Dr. Kranzler. 'It has been estimated that less than 10% of patients are currently receiving treatment for AUD and that 2% or less are being treated with any of the 3 medications approved for AUD in the US1. These medications were approved decades ago and have limited beneficial effects and inadequate compliance rates. Thus, there is an urgent need for new therapies for AUD.' 'There are compelling data that GLP-1 agents may reduce the craving for alcohol in addition to reducing food consumption,' said Scott Harris, M.D., Chief Medical Officer of Altimmune. 'In a preclinical hamster model of free-choice alcohol intake, pemvidutide demonstrated a greater than 80% reduction in alcohol preference after the initiation of treatment2. Importantly, AUD is the precursor for alcohol liver disease (ALD), a disease characterized by excess liver fat, liver inflammation and fibrosis with features similar to MASH. In addition, obesity is a major risk factor for MASH, AUD and ALD, and because excess alcohol is a known risk factor for hypertension and dyslipidemia, patients with AUD could benefit further from the metabolic effects of pemvidutide.' About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on X Forward-Looking StatementAny statements made in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, the timing of key milestones for our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and our other filings with the SEC, which are available at Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@ Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@ Media Contact:Jake RobisonInizio Evoke, BiotechPhone: 1 SAMHSA 2023 NSDUH Survey 2 Altimmune R&D Day Presentation, slide #47 This press release was published by a CLEAR® Verified in to access your portfolio
Yahoo
19-05-2025
- Automotive
- Yahoo
One hospitalized after car rolls on side in Montgomery County
MONTGOMERY COUNTY, Md. () — Responders took one person to the hospital Saturday after their car rolled over in Gaithersburg. In a post on X just after 9:30 a.m., Pete Piringer with the Montgomery County Fire and Rescue Service said crews were responding to a collision on Route 355 at N Frederick Avenue and Montgomery Village Avenue. At the scene, they found a car that had turned on its side. Crews rescue two people 'clinging' to tree in Potomac River, officials say Responders worked to help the driver out of the car before taking them to the hospital for treatment of non-life-threatening injuries, Piringer said. As a result of the crash, some lanes were blocked as crews cleared the scene. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
